Sparks commentary - Dicot Pharma

Healthcare

Sparks - Dicot Pharma

More on this equity
Dicot Pharma (STO: DICOT) – Phase IIb gets underway
Published by Jyoti Prakash, CFA

Dicot Pharma has initiated Part I of its Phase IIb study of LIB-01 in erectile dysfunction (ED) with the first patient screened at a US centre, marking an important step towards dose optimisation and broader clinical validation ahead of Phase III. Part I will establish the highest dose for evaluation in Part II, with completion expected in Q127. The overall adaptive study will enrol at least 200 patients across the US and Europe, assessing three dose levels under a repeated monthly dosing regimen. We note that while the prior Phase IIa demonstrated encouraging durability of effect, lasting up to eight weeks, statistically significant placebo-adjusted improvements were primarily observed in patients with moderate ED. Phase IIb will therefore be critical in establishing reproducible efficacy across a broader patient population and validating LIB-01’s differentiation from conventional on-demand treatments such as PDE5 inhibitors. With the study fully funded by the SEK231.3m raise in June 2026, attention now shifts to Part I completion and subsequent progression into the efficacy-focused Part II, potentially strengthening Phase III readiness and partnering appeal.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.